cyclic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
For services to Aviation. Elsie Macpherson. For services to Mentally Ill People. Maureen S. Macmillan, Chairman, City of Edinburgh Children's Panel Advisory Committee. For services to Young People. Stuart Macredie, lately Headteacher, St Albans Junior and Infant School, Wickersley, Rotherham. For services to Education. The Reverend Robert James Magee. For services to Community Relations. Alan Roderick Males. For services to Architecture. Patricia Anne Mansfield. For services to the community in Leicester. Constance May Marcroft. For services to Deaf People in Sheffield. Leslie George Mardell, Administrative Officer, London Fire and Civil Defence Authority. For services to the Fire Service. Samuel Steele Marsden. For services to Agriculture. Derek Marshall, Chief Executive, South Humber Business Advice Centre Ltd. For services to Business. Keith John Martin. For political and public service Rosemary Elizabeth Massey, Office Manager, Lord Chancellor's Department. Stanley Thomas Massey. For services to the community in Havant, Hampshire. Carole Kathleen Masters, Higher Executive Officer, Department of Social Security. William James McAlpine. For services to Scouting. Joan McCallion, Typist, Ministry of Defence. Rachel McClean. For services to Training. Isa McComb. For services to Housing. William Rae McCrindle, Chairman, McCrindle Group. For services to the Engineering Industry. David McCubbin, Compliance Manager, Board of Inland Revenue. Norman Charles John McElroy. For services to the Police. William McGowan, Farmer. For services to the Cattle Industry in Fife.
=== Causality === Early case-control studies clearly showed a close association between smoking and lung cancer, but contemporary doctors and scientists did not feel evidence existed for causality. Follow-up large prospective cohort studies in the early 1950s showed clearly that smokers died faster, and were more likely to die of lung cancer, cardiovascular disease, and a list of other diseases which lengthened as the studies continued The British Doctors Study, a longitudinal study of some 40,000 doctors, began in 1951. By 1954 it had evidence from three years of doctors' deaths, based on which the government issued advice that smoking and lung cancer rates were related (the British Doctors Study last reported in 2001, by which time there were approximately 40 linked diseases). The British Doctors Study demonstrated that about half of the persistent cigarette smokers born in 1900–1909 were eventually killed by their addiction.
=== 24 April === Russian forces stopped an attack on the Black Sea Fleet base at Sevastopol. The Russian defence ministry said that "three unmanned high-speed boats" were destroyed. Ukraine did not comment on the attack.
==== Neurodegeneration ==== Research has been conducted on the effects of stem cells on animal models of brain degeneration, such as in Parkinson's disease, Amyotrophic lateral sclerosis, and Alzheimer's disease. Preliminary studies related to multiple sclerosis have been conducted, and a 2020 phase 2 trial found significantly improved outcomes for mesenchymal stem cell treated patients compared to those receiving a sham treatment. In January 2021 the FDA approved the first clinical trial for an investigational stem cell therapy to restore lost brain cells in people with advanced Parkinson's disease. Healthy adult brains contain neural stem cells, which divide to maintain general stem-cell numbers, or become progenitor cells. In healthy adult laboratory animals, progenitor cells migrate within the brain and function primarily to maintain neuron populations for olfaction (the sense of smell). Pharmacological activation of endogenous neural stem cells has been reported to induce neuroprotection and behavioral recovery in adult rat models of neurological disorders.
Sources: en.wikipedia.org
== Overview == Permafrost mummies provide crucial insights into the physiology and life histories of Pleistocene organisms, due to how well the preservation process keeps the specimens from decomposing. The constant presence of permafrost is able to preserve the soft tissues of organisms through a process similar to freeze-drying. With such complete preservation of tissues, it is possible to determine numerous things from the such as: DNA, eDNA, evolutionary history, gut contents, and trophic dynamics. Studies have even shown that the process is so complete there is evidence of nucleic activity. Some of these specimens are on display at the Kingdom of the Permafrost museum near Yakutsk. (E) - denote an extinct species or subspecies
Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy. This is partly due to a number of complications with which it is associated, including two to four times the risk of cardiovascular disease, including ischemic heart disease and stroke; a 20-fold increase in lower limb amputations, and increased rates of hospitalizations. In the developed world, and increasingly elsewhere, type 2 diabetes is the largest cause of nontraumatic blindness and kidney failure. It has also been associated with an increased risk of cognitive dysfunction and dementia through disease processes such as Alzheimer's disease and vascular dementia. Other complications include hyperpigmentation of skin (acanthosis nigricans), sexual dysfunction, diabetic ketoacidosis, and frequent infections. There is also an association between type 2 diabetes and mild hearing loss.
== Case studies: environmental impact on hemocyanin levels == A 2003 study of the effect of culture conditions of blood metabolites and hemocyanin of the white shrimp Litopenaeus vannamei found that the levels of hemocyanin, oxyhemocyanin in particular, are affected by the diet. The study compared oxyhemocyanin levels in the blood of white shrimp housed in an indoor pond with a commercial diet with that of white shrimp housed in an outdoor pond with a more readily available protein source (natural live food) as well. Oxyhemocyanin and blood glucose levels were higher in shrimp housed in outdoor ponds. It was also found that blood metabolite levels tended to be lower in low activity level species, such as crabs, lobsters, and the indoor shrimp when compared to the outdoor shrimp. This correlation is possibly indicative of the morphological and physiological evolution of crustaceans. The levels of these blood proteins and metabolites appear to be dependent on energetic demands and availability of those energy sources.
Sources: en.wikipedia.org
== TNF inhibitors == TNF inhibitors are commonly the first drug prescribed when a patient begins biologic therapy. They have the most extensive history of clinical evidence because they have been available the longest, are the most accessible, and are often the least expensive. Initially, it was thought that TNF inhibitors inactivate the proinflammatory cytokine by direct neutralization, but TNF signaling is a very complex process. Many recent studies suggest that TNF inhibitors may act with a more complex mechanism than simple blockade. They are all administered systemically either subcutaneously or intravenously.
Morpholino nucleic acids replace the sugar with a morpholine component, and the phosphate with a phosphorodiamidate component. Miravirsen is an antisense drug candidate that incorporates both locked nucleic acid sugar components and phosphorothioate groups.
=== General === KOR agonism seems to functionally oppose multiple effects mediated by μ-opioid receptors (MOR) and δ-opioid receptors (DOR), including analgesia, tolerance, euphoria, and memory regulation. Activation of KOR by dynorphins during stress exposure has been shown to induce dysphoria, aversion, and negative affective states in both human and non-human subject. This contrasts with activation of MOR, which is associated with mood elevation and producing hedonic effects. Consequently, the KOR system has traditionally been conceptualized as mediating anti-reward processes and negative reinforcement, representing a functional counterpart to MOR in terms of behavioral and affective outcomes. However, recent research highlights a more nuanced role for KOR signaling, implicating it in a spectrum of complex behaviors and neural processes that extend beyond a strictly dichotomous and unidimensional frameworks, including functions independent of hedonic tone within reward processing. Centrally active KOR agonists have distinct, atypical dissociative hallucinogenic effects, as exemplified by salvinorin A (the active constituent in Salvia divinorum). The experiences include: dissociation, incapacitation, psychotomimesis, profound alterations in interoception, somatic sensations, visual and auditory hallucinations, synesthesia (particularly visual-proprioceptive binding), sedation, analgesia, anti-inflammation, neuroprotection, memory impairment, anti-addiction, aversion, dysphoria, anxiogeny, both antidepressant and depressogenic effect.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.